Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: A 6-month randomised controlled trial

British Journal of Nutrition

Volumn 107, Issue 11, 2012, Pages 1682-1693

  Sinn, Natalie ^a   Milte, Catherine M ^a   Street, Steven J ^b   Buckley, Jonathan D ^a   Coates, Alison M ^a   Petkov, John ^a   Howe, Peter R C ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Dementia; Depression; DHA; EPA; Mild cognitive impairment; n 3 Fatty acids

Indexed keywords

DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; LINOLEIC ACID; PLACEBO; SAFFLOWER OIL;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEFECATION DISORDER; DEMENTIA; DEPRESSION; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DIVERTICULITIS; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHROCYTE; EXECUTIVE FUNCTION; FEMALE; FLATULENCE; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; GERIATRIC DEPRESSION SCALE; HUMAN; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL HEALTH; MILD COGNITIVE IMPAIRMENT; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SELF REPORT; TREATMENT DURATION;

EID: 84950170862     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114511004788     Document Type: Article

References (53)

1. Blennow K, de Leon MJ & Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
2. Ferri CP, Prince M, Brayne C, et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117.
3. Gauthier S, Reisberg B, Zaudig M, et al. (2006) Mild cognitive impairment. Lancet 367, 1262-1270.
4. Chertkow H (2002) Mild cognitive impairment. Curr Opin Neurol 15, 401-407.
5. Gabryelewicz T, Styczynska M, Pfeffer A, et al. (2004) Prevalence of major and minor depression in elderly persons with mild cognitive impairment-MADRS factor analysis. Int J Geriatr Psychiatry 19, 1168-1172.
6. Modrego P & Ferrández J (2004) Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type. Arch Neurol 61, 1290-1293.
7. Simopoulos AP (1991) Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 54, 438-463.
8. Assisi A, Banzi R, Buoinocore C, et al. (2006) Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. Int Clin Psychopharmacol 21, 319-336.
9. Chalon S (2006) Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 75, 259-269.
10. Haag M (2003) Essential fatty acids and the brain. Can J Psychiatry 48, 195-203.
11. Hibbeln JR, Ferguson TA & Blasbalg TL (2006) Omega-3 fatty acid deficiencies in neurodevelopment, aggression and autonomic dysregulation: opportunities for intervention. Int Rev Psychiatry 18, 107-118.
12. Simopoulos AP (1999) Essential fatty acids in health and chronic disease. Am J Clin Nutr 70, Suppl. 3, 560S-569S.
13. Yehuda S, Rabinovitz S, Carasso RL, et al. (2002) The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol Aging 23, 843-853.
14. Söderberg M, Edlund C, Kristensson K, et al. (1991) Fatty acid composition of brain phospholipids in aging and in Alzheimer's Disease. Lipids 26, 421-425.
15. Sinn N, Milte C & Howe PRC (2010) Oiling the brain: a review of randomised controlled trials of omega-3 fatty acids in psychopathology across the lifespan. Nutrients 2, 128-170.
16. Terano T, Fujishiro S, Ban T, et al. (1999) Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. Lipids 34, Suppl., S345-S346.
17. Yehuda S, Rabinovitz S, Carasso RL, et al. (1996) Essential fatty acids preparation (SR-3) improves Alzheimer's patients quality of life. Int J Neurosci 87, 141-149.
18. Chiu C-C, Su K-P, Cheng T-C, et al. (2008) The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuro-Psychopharmacol Biol Psychiatry 32, 1538-1544.
19. Freund-Levi Y, Basun H, Cederholm T, et al. (2008) Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 23, 161-169.
20. Kotani S, Sakaguchi E, Warashina S, et al. (2006) Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 56, 159-164.
21. Dangour AD, Allen E, Elbourne D, et al. (2010) Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-bind, controlled trial. Am J Clin Nutr 91, 1725-1732.
22. van de Rest O, Geleijnse JM, Kok FJ, et al. (2008) Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology 71, 430-438.
23. Yurko-Mauro K (2010) Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline. Curr Alzheimer Res 7, 190-196.
24. Sinclair AJ, Begg D, Mathai M, et al. (2007) Omega 3 fatty acids and the brain: review of studies in depression. Asia Pac J Clin Nutr 16, Suppl. 1, 391-397.
25. Winblad B, Palmer K, Kivipelto M, et al. (2004) Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Int Med 256, 240-246.
26. Wechsler D (1997) Wechsler Memory Scale-III. Administration and Scoring Manual. San Antonio, TX: Psychological Corporation.
27. Kalbe E, Kessler J, Calabrese P, et al. (2004) DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry 19, 136-143.
28. Altman DG & Bland JM (2005) Treatment allocation by minimisation. Br Med J 330, 843.
29. Sheikh JI & Yesavage JA (1986) Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In Clinical Gerontology: A Guide to Assessment and Intervention, pp. 165-173. New York: The Haworth Press.
30. Sanson-Fisher RW & Perkins JJ (1998) Adaptation and validation of the SF-36 Health Survey for use in Australia. J Clin Epidemiol 51, 961-967.
31. Raschetti R, Albanese E, Vanacore N, et al. (2007) Cholinesterase inhibitors in mild cognitive impairment: a systematic review of RCTs. Pub Libr Science: Med 4, 1818-1828.
32. Gilewski MJ & Zelinski EM (1988) Memory Functioning Questionnaire. Psychopharmacol Bull 24, 665-670.
33. Lezak MD (1995) Neuropsychological Assessment, 3rd ed. New York: Oxford University Press.
34. Wechsler D (1997) Wechsler Adult Intelligence Scale, 3rd ed. San Antonio, TX: Psychological Corporation.
35. Kent P, Bryan J & Clark M (2004) Preclinical signs of dementia in a community sample: a longitudinal analysis. Brain Impairment 5, 108.
36. Sachs TL, Clark CR, Pols RG, et al. (1991) Comparability and stability of performance of six alternative forms of the Dodrill-Stroop Color-Word Test. Clin Neuropsychol 54, 1063-1070.
37. Bryan J, Luszcz M & Crawford JR (1997) Verbal knowledge and speed of information processing as mediators of age differences in verbal fluency performance among older adults. Psychol Aging 12, 473-478.
38. Rosen WG (1980) Verbal fluency in aging and dementia. J Clin Exp Neuropsychol 2, 135-146.
39. Bligh EG & Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Physiol Pharmacol 37, 911-917.
40. Folch J, Lees M & Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226, 497-509.
41. Lepage G & Roy CC (1986) Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 27, 114-120.
42. Hedeker D & Gibbons RD (2006) Longitudinal Data Analysis. New Jersey: John Wiley & Sons Inc.
43. Tabachick B & Fidell L (2001) Using Multivariate Statistics. Needham Heights, MA: Allyn & Bacon.
44. Osborne JW & Overbay A (2004) The power of outliers (and why researchers should always check for them). Pract Assess Res Eval 9. (Retrieved 25 May 2011 from http://PAREonline. net/getvn.asp?v9&n6).
45. Norman GR, Sloan JA & Wyrwich KW (2003) Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41, 582-592.
46. Milte C, Sinn N, Street SJ, et al. (2011) Erythrocyte polyunsaturated fatty acid status, memory, cognition and mood in older adults with mild cognitive impairment and healthy controls. Prostaglandins Leukot Essent Fatty Acids 84, 153-161.
47. Sinn N & Howe PRC (2008) Mental health benefits of omega-3 fatty acids may be mediated by improvements in cerebral vascular function. Biosci Hypotheses 1, 103-108.
48. Nemets B, Stahl Z & Belmaker RH (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 159, 477-479.
49. Peet M & Horrobin DF (2002) A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 59, 913-919.
50. Meyer B, Grenyer BFS, Crowe T et al. (editors) (2004) Improvement of major depression is associated with increased erythrocyte DHA-subset analysis in a doubleblind omega-3 supplementation trial. International Society for the Study of Fatty Acids and Lipids (ISSFAL), 27 June-1 July, Brighton, UK.
51. Grenyer BFS, Crowe T, Meyer B, et al. (2007) Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 31, 1393-1396.
52. Su K-P, Huang S-Y, Chiu C-C, et al. (2003) Omega-3 fatty acids in major depressive disorder: a preliminary doubleblind, placebo-controlled trial. Eur Neuropsychopharmacol 13, 267-271.
53. Marangell LB, Martinez JM, Zboyan HA, et al. (2003) A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 160, 996-998.